Xenios Advances Novel i-cor Synchronized Cardiac-Assist System In Europe
Executive Summary
Xenios announced in late November that it had received CE mark for i-cor, an acute mechanical circulatory support device that provides assistance to a failing heart with an external, heartbeat-synchronized system that generates an artificial pulse. The company believes i-cor will open up new therapy options for the hundreds of thousands of patients in acute heart failure (cardiogenic shock) and in those undergoing high-risk interventions in the cath lab – a market opportunity estimated at $5 billion annually in the US and Europe alone.
You may also be interested in...
Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.